Foundation Medicine, Inc.
One Kendall Square
167 articles with Foundation Medicine, Inc.
This is the largest fund in the 12 years Third Rock has been in existence. The company indicates it will use the money to seed 10 to 12 life science companies.
Bayer and Foundation Medicine announce global collaboration to develop next-generation sequencing (NGS)-based companion diagnostics in oncology
Bayer AG and Foundation Medicine, Inc. announced a global collaboration for the development and commercialization of NGS-based companion diagnostics.
The first project the companies aim to develop is a companion diagnostic for Vitrakvi, the only TRK inhibitor approved in the U.S. for patients with TRK fusion cancer across all solid tumors.
For its 2019 list of the top 50 most innovative companies, Fast Company selected 10 from the biotech industry that are having a significant impact on the treatment of patients. The first five are highlighted.
Breakthrough Approval Enables Patient Access to Comprehensive Genomic Profiling and Advances Oncology Therapy Development in Japan
Novartis to Leverage Foundation Medicine’s Molecular Information Solutions to Develop Companion Diagnostics for Cancer Therapies
Foundation Medicine Introduces FoundationOne®Liquid, the Latest Advance in the Company’s Liquid Biopsy Test for Solid Tumors in Patients with Advanced Cancer
FoundationOne Liquid analyzes 70 genes known to drive cancer growth and reports microsatellite instability high (MSI-high) status to inform the use of precision oncology treatments, including immunotherapies, with a simple blood draw
9/5/2018On August 29, Chicago-based Tempus, which focuses on data analytics for molecular and clinical data, announced it had raised $110 million in Series E financing. This brought total money raised so far to $320 million. This also gave the company a valuation of $2 billion.
Foundation Medicine Publishes New Data in Nature Medicine Supporting Blood Tumor Mutational Burden (bTMB) as a Novel Predictor of Response to Cancer Immunotherapy
New publication details Foundation Medicine’s assay’s ability to measure bTMB and to identify patients who may benefit from anti-PD-L1 therapy
7/31/2018Only a matter of days after Roche filed its second-quarter financial report, it’s had plenty of news to report.
Investors love their takeover rumors, and with biopharma having a good year for mergers and acquisitions, there’s been plenty to keep them busy. Here’s two takeover rumors that came out of Spanish media group Intereconomia.
Foundation Medicine, Inc. and Guardant Health, Inc. announced an agreement to settle a patent infringement lawsuit brought by Foundation Medicine against Guardant concerning U.S. Patent No. 9,340,830.
Both “rare cancers” and “sub-populations of cancers” present a challenge to companies conducting clinical trials—finding enough patients for those trials.
Three years after acquiring a majority stake Foundation Medicine, Pharma giant Roche has agreed to buy up all outstanding shares for about $2.4 billion and bring the company’s sequencing diagnostics platform under the Roche umbrella.
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that members of the company's management team will present at the following upcoming investor conferences:
Foundation Medicine and Collaborators to Present New Data at ASCO 2018 Supporting Comprehensive Genomic Profiling (CGP) to Inform Personalized Approaches in Cancer Care
Foundation Medicine, Inc. announced that new data generated from its comprehensive genomic profiling (CGP) assays will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting from June 1-5, 2018 in Chicago.
Pan-Cancer MSI Companion Diagnostic for KEYTRUDA® (pembrolizumab) Planned for Inclusion on FoundationOne CDx™
Foundation Medicine Launches Gene Expression Profiling Program to Identify Known and Novel Biomarkers in Advanced Cancer
Foundation Medicine, Inc. announced a comprehensive gene expression profiling (GEP) program to support precision oncology clinical research and development.
Foundation Medicine reported financial and operational results for the first quarter ended March 31, 2018.
Foundation Medicine’s New Liquid Biopsy Assay Granted Breakthrough Device Designation by U.S. Food and Drug Administration
The new assay will include more than 70 genes and genomic biomarkers for microsatellite instability (MSI) and blood tumor mutational burden (bTMB).